Table 4.
Drug, sexual risk behaviors and STD prevalence among enrolled participants (N=557)
| Drug and sexual risk behaviors | N (%) |
|---|---|
| ≥ 5 drinks/day when drinking | 64 (11.5) |
| Drug use, past 3 mo. | |
| Poppers or other inhalants | 258 (46.3) |
| Powder cocaine/crack | 112 (20.1) |
| Methamphetamines | 83 (14.9) |
| Club drugsa | 129 (23.2) |
| ED drugsb | 175 (32.1) |
| Marijuana | 244 (43.8) |
| Injected drugs last 3 mo. | 10 (1.8) |
| Has primary partner | |
| Yes – HIV positive | 132 (23.7) |
| Yes – HIV negative | 129 (23.2) |
| Yes – Unsure of HIV status | 6 (1.1) |
| No | 290 (52.1) |
| # male condomless anal sex partners, last 3 mo | |
| 0 | 75 (13.5) |
| 1 | 117 (21.0) |
| 2-5 | 233 (41.8) |
| 6-9 | 59 (10.6) |
| ≥10 | 71 (13.1) |
| # male condomless anal sex episodes, last 3 mo | |
| 0 | 77 (13.8) |
| 1 | 27 (4.9) |
| 2-5 | 130 (23.3) |
| 6-9 | 75 (13.5) |
| ≥10 | 248 (44.5) |
| Condomless anal sex | |
| None | 77 (13.8) |
| Insertive only | 126 (22.6) |
| Any receptive | 354 (63.6) |
| Condomless receptive anal sex, last 3 mo. | |
| None | 203 (36.5) |
| With HIV negative only | 147 (26.4) |
| With unknown serostatus | 75 (13.5) |
| With any HIV positive | 132 (23.7) |
| Any female condomless anal or vaginal sex partners | 12 (2.2) |
| Exchange sex last 3 months | 30 (5.4) |
| Perceived likelihood of getting HIV in next year | |
| <5% | 110 (20.1) |
| 5-25% | 152 (27.8) |
| 26-50% | 196 (35.8) |
| >50% | 89 (16.3) |
| Prevalence of STDs | |
| Early syphilis | 24 (4.3) |
| Primary | 5 (0.9) |
| Secondary | 9 (1.6) |
| Early latent | 10 (1.8) |
| Gonorrhea (any site) | 86 (15.4) |
| Chlamydia (any site) | 75 (13.5) |
| Rectal gonorrhea or chlamydia | 92 (16.6) |
a
Ecstasy, gamma-hydroxybutyrate (GHB), or ketamine
b
Recreational use of medications to enhance erectile dysfunction, including sildenafil, vardenafil, and tadalafil